For the quarter ended September 2023, HCA Healthcare (HCA - Free Report) reported revenue of $16.21 billion, up 8.3% over the same period last year. EPS came in at $3.91, compared to $3.93 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $15.77 billion, representing a surprise of +2.80%. The company delivered an EPS surprise of -1.51%, with the consensus EPS estimate being $3.97.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how HCA performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue per Equivalent Admission: $16,915 versus $16,547.13 estimated by four analysts on average.
- Equivalent Admissions: 958.5 million compared to the 944.34 million average estimate based on four analysts.
- Number of hospitals: 183 versus the three-analyst average estimate of 182.
- Equivalent Patient Days: 4,655.25 thousand compared to the 4,577.18 thousand average estimate based on three analysts.
- Admissions: 537.94 million versus the two-analyst average estimate of 530.75 million.
- Average Length of Stay: 5 compared to the 5 average estimate based on two analysts.
- Licensed Beds at End of Period: 49,279 versus the two-analyst average estimate of 49,148.
- Same Facility - Equivalent Admissions: 946.44 thousand versus the two-analyst average estimate of 936.68 thousand.
- Same Facility - Revenue per Equivalent Admission: $16,880 compared to the $16,791.54 average estimate based on two analysts.
- Patient Days: 2,612.44 Days versus the two-analyst average estimate of 2,509.94 Days.
- Number of freestanding outpatient surgery centers: 126 versus the two-analyst average estimate of 126.
View all Key Company Metrics for HCA here>>>Shares of HCA have returned -5.3% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
For the quarter ended September 2023, HCA Healthcare (HCA - Free Report) reported revenue of $16.21 billion, up 8.3% over the same period last year. EPS came in at $3.91, compared to $3.93 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $15.77 billion, representing a surprise of +2.80%. The company delivered an EPS surprise of -1.51%, with the consensus EPS estimate being $3.97.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how HCA performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue per Equivalent Admission: $16,915 versus $16,547.13 estimated by four analysts on average.
- Equivalent Admissions: 958.5 million compared to the 944.34 million average estimate based on four analysts.
- Number of hospitals: 183 versus the three-analyst average estimate of 182.
- Equivalent Patient Days: 4,655.25 thousand compared to the 4,577.18 thousand average estimate based on three analysts.
- Admissions: 537.94 million versus the two-analyst average estimate of 530.75 million.
- Average Length of Stay: 5 compared to the 5 average estimate based on two analysts.
- Licensed Beds at End of Period: 49,279 versus the two-analyst average estimate of 49,148.
- Same Facility - Equivalent Admissions: 946.44 thousand versus the two-analyst average estimate of 936.68 thousand.
- Same Facility - Revenue per Equivalent Admission: $16,880 compared to the $16,791.54 average estimate based on two analysts.
- Patient Days: 2,612.44 Days versus the two-analyst average estimate of 2,509.94 Days.
- Number of freestanding outpatient surgery centers: 126 versus the two-analyst average estimate of 126.
View all Key Company Metrics for HCA here>>>Shares of HCA have returned -5.3% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Get the latest research report on HCA - FREE